Answers are grounded in this paper and cite their sources.
Background and Aims Contrast‐associated acute kidney injury (CA‐AKI) is a major complication following coronary procedures. We aimed to evaluate the effectiveness of a combination of urine flow rate‐(UFR) guided hydration (RenalGuard TM ) and device‐based contrast media (CM) reduction (DyeVert TM ) in CA‐AKI prevention. Methods Stable high‐risk patients undergoing coronary procedures with the use of DyeVert TM and RenalGuard TM were prospectively included ( Combined group) and matched with a similar cohort of patients treated only with RenalGuard TM in whom CM volume was controlled by operator‐dependent strategies ( Control group). CA‐AKI was defined as a serum creatinine increase ≥0.3 mg/dL at 48 h. Results Overall, 55 patients were enrolled and matched with comparable controls. Patients in the Combined group were exposed to a lower CM dose ( Control : 55 [30–90] mL vs. Combined : 42.1 [24.9–59.4] mL; p = 0.024). A significant interaction was found between treatment allocation and serum creatinine changes ( p = 0.048). CA‐AKI occurred in five (9.1%) patients in the Combined group and in 14 (25.4%) patients in the Control group (OR 0.29, 95% CI [0.09–0.88]). Conclusions A combined strategy of device‐based CM reduction plus UFR‐guided hydration is superior to operator‐dependent CM sparing strategies plus UFR‐guided hydration in preventing CA‐AKI in high‐risk patient.
No takes yet. Share an insight, caveat, or question.
Paolucci et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: